|
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
|
2R44CA210817-02
|
$1,101,350
|
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
Innovation Corp Program and Commercialization Planning for Endoscopic Flexible Pancreatic Tumor Ablation System with Reduced Force Effector and Specialized Ablation Zone
|
3R43CA225169-01S1
|
$49,999
|
|
SNOOK, KEVIN
|
ACTUATED MEDICAL, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
2R44CA200161-02A1
|
$1,000,000
|
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation
|
1R43CA232977-01
|
$298,444
|
|
MARLEAU, ANNETTE
|
AETHLON MEDICAL, INC.
|
|
Training African Pathologists in Cancer Diagnosis
|
1R13CA232439-01
|
$38,120
|
|
WILSON, MICHAEL
|
AFRICAN STRATEGIES /ADVANCING PATHOLOGY
|
|
HIV/HPV Cancer Prevention, Treatment & Pathogenesis: Rwanda/Einstein Consortium
|
5U54CA190163-04
|
$701,778
|
$56,142
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Therapeutic peptide for hepatocellular carcinoma
|
1R43CA232947-01
|
$299,983
|
|
PANDEY, NIRANJAN
|
ASCLEPIX THERAPEUTICS, LLC
|
|
Create three-member project team to refine commercialization plans for AML-Mutation Counter, a tool to detect residual and recurrent leukemia.
|
3R41CA213690-01S1
|
|
|
KAUFMANN, WILLIAM
|
ASYSTBIO LABORATORIES, LLC
|
|
DT-EGF Toxic Fusion Protein for the Treatment of Bladder Cancer
|
1R44CA232963-01
|
$299,937
|
|
GLODE, MIKE
|
AURORA ONCOLOGY, INC.
|
|
Rapid Non-Viral Platform for Generation of Genetically Modified T Cells for Therapy
|
1R44CA233143-01
|
$218,588
|
|
LAMPI HERMANSON, DAVID
|
B-MOGEN BIOTECHNOLOGIES, INC.
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S1
|
$118,875
|
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S2
|
$249,997
|
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Role of Vitamin B5 and Coenzyme A Metabolism in PI3K Driven Tumorigenesis
|
4R00CA194314-03
|
$249,000
|
|
DIBBLE, CHRISTIAN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Tissue-specific genetic interactions in cancer
|
1R01CA232372-01
|
$505,643
|
|
HAIGIS, KEVIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Parallel and high throughput isolation of cancer cell derived extracellular vesicles
|
1R43CA232848-01
|
$239,138
|
|
MULLER, ROLF
|
BIOFLUIDICA, INC
|
|
Increased sensitivity of minimal residual disease monitoring using peripheral blood in pediatric patients with acute lymphoblastic leukemia
|
1R44CA224848-01A1
|
$348,768
|
|
MULLER, ROLF
|
BIOFLUIDICA, INC
|
|
Cancer Imaging and Therapy Analysis Platform (CITAP)
|
2R44CA213601-02
|
$817,362
|
|
GARGESHA, MADHUSUDHANA
|
BIOINVISION, INC.
|
|
Biomedical Engineering Society Annual Meeting
|
1R13EB026960-01
|
$5,000
|
|
SETTON, LORI
|
BIOMEDICAL ENGINEERING SOCIETY
|
|
Detection of Methylation and Translocation Events by Novel Genomic Technologies
|
3R43CA214386-01S1
|
$50,000
|
|
PEYTAVI, REGIS
|
BLUENOVO BIOSYSTEMS, INC.
|
|
Development of a novel Antibody Drug Conjugate for the treatment of pancreaticcancer
|
1F30CA220843-01A1
|
$49,524
|
|
GROMISCH, CHRISTOPHER
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Determining the roles of the Hippo pathway kinases LATS1 and LATS2 in mammary gland homeostasis and disease
|
1F31CA232683-01
|
$44,524
|
|
KERN, JOSEPH
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
The novel PRMT5-substrate adaptor interface provides a therapeutic target in MTAP null tumors
|
1F32CA232543-01
|
$58,654
|
|
MULVANEY, KATHLEEN
|
BROAD INSTITUTE, INC.
|
|
Supine Breast MRI Standardization for Breast Cancer Locator
|
1R44CA232862-01
|
$221,343
|
|
KRISHNASWAMY, VENKATARAMANAN
|
CAIRNSURGICAL, INC.
|
|
CapioCyte circulating tumor cell assay as a biomarker for cancer immunotherapy response
|
1R43CA232924-01
|
$209,801
|
|
MILLER, STEVEN
|
CAPIO BIOSCIENCES, INC.
|
|
Develop a rapid, efficient and low cost extracellular vesicles isolation method toward non-invasive non-small cell lung cancer molecular analysis
|
1R43CA228847-01A1
|
$300,000
|
|
HE, HONGZHANG
|
CAPTIS DIAGNOSTICS
|
|
Transient anti-BCMA CAR T-cells for Treatment of Multiple Myeloma
|
1R43CA221432-01A1
|
$299,042
|
|
STEWART, CHARLES
|
CARTESIAN THERAPEUTICS, INC.
|
|
Radiogenomic tools for prediction of breast cancer neo-adjuvant chemotherapy response from pre-treatment MRI
|
1F31CA221383-01A1
|
$42,074
|
|
BRAMAN, NATHANIEL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Targeting pancreatic cancers metabolic addiction to HuR
|
1R37CA227865-01A1
|
$401,484
|
|
WINTER, JORDAN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Clinical Translation of a Caveolae Targeting Antibody for Enhancing Cancer Drug Delivery
|
1R41CA228841-01A1
|
$300,001
|
|
YANG, CHUN
|
CAVATAR, LLC
|
|
Specificity and safety of a targeted therapy against triple negative breast cancer
|
1R43CA224750-01A1
|
$300,000
|
|
IVANOVSKA, IRENA
|
CELDARA MEDICAL, LLC
|
|
Chemically produced neural progenitors loaded with ferumoxide-protamine sulfate complex for visualization of gliomas
|
1R43CA228726-01A1
|
$300,000
|
|
ALEXANIAN, ARSHAK
|
CELL REPROGRAMMING AND THERAPEUTICS, LLC
|
|
Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood Cancers
|
1U54CA232568-01
|
$12,197,183
|
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Cassette exons in neoplastic pro-B-cells: implications for immunotherapy
|
1U01CA232563-01
|
$2,931,750
|
|
THOMAS-TIKHONENKO, ANDREI
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Highly Sensitive Chimerism Testing to Detect Early Leukemia Relapse Post-Allo-Transplantation
|
1R41CA232805-01
|
$173,566
|
|
KANAAN, SAMI
|
CHIMEROCYTE, INC.
|
|
Pre-IND development of CBT-15 monoclonal antibody therapy against renal cell cancer
|
1R44CA228895-01A1
|
$298,835
|
|
SUREBAN, SRIPATHI
|
COARE HOLDINGS, INC.
|
|
Super-Competition as a Mechanism for Preneoplastic Field Growth
|
1F31CA228451-01A1
|
$44,524
|
|
CRAWLEY, TIMOTHY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
An integrated theranostic system for breast cancer
|
1R01CA228275-01A1
|
$566,633
|
|
KONOFAGOU, ELISA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Structural and Functional Characterization of the Epithelial Calcium Channel TRPV6
|
1F31CA232391-01
|
$44,524
|
|
MCGOLDRICK, LUKE
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Role of Cancer-Associated Fibroblasts in Cholangiocarcinoma
|
1R01CA228483-01A1
|
$634,470
|
|
SCHWABE, ROBERT
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S2
|
$60,000
|
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Novel Immuno-oncology Strategy for Targeted Cytotoxic Lymphocyte Activation
|
1R41CA224520-01A1
|
$288,105
|
|
KRUPNICK, ALEXANDER
|
COURIER THERAPEUTICS, INC.
|
|
AML differentiation therapy
|
1R43CA228780-01A1
|
$223,080
|
|
HOU, YONGCHUN
|
CURONBIOTECH, INC.
|
|
The molecular basis of substrate specificity for a small molecule ubiquitin ligase complex
|
1F32CA232772-01
|
$58,654
|
|
FAUST, TYLER
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA023108-39S1
|
$100,606
|
|
LEACH, STEVEN
|
DARTMOUTH COLLEGE
|
|
Defining a Transcriptional Signatures of Tissue-Resident T-cells in Melanoma through Single Cell RNA-seq
|
1F31CA232554-01
|
$44,524
|
|
MOLODTSOV, ALEKSEY
|
DARTMOUTH COLLEGE
|
|
Role of SNF5 in regulating SWI/SNF complex assembly & targeting in rhabdoid tumor
|
4R00CA197640-03
|
$249,000
|
|
WANG, XIAOFENG
|
DARTMOUTH COLLEGE
|
|
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN: A Phase II Clinical Trial in Adolescents/Young Adults (AYA)with CNS Malignancies
|
2R44CA203351-03
|
$240,368
|
|
MORGAN, LEE
|
DEKK-TEC, INC.
|
|
A Non-Contact Optical Patient and Beam Dosimetry System for Continuous in vivo Radiotherapy Verification
|
1R44CA232879-01
|
$252,666
|
|
WARE, WILLIAM
|
DOSEOPTICS, LLC
|
|
Cancer Center Support Grant
|
3P30CA014236-44S1
|
$59,375
|
|
KASTAN, MICHAEL
|
DUKE UNIVERSITY
|
|
Cancer Center Support Grant
|
3P30CA014236-44S2
|
$249,377
|
|
KASTAN, MICHAEL
|
DUKE UNIVERSITY
|
Total relevant funding to Penis for this search: $651,482
|